Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Comparison of amitriptyline with stabilization splint and placebo in chronic TMD patients: a pilot study. (CROSBI ID 264885)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Alajbeg, Iva ; Borić Brakus, Ratka ; Brakus, Ivan Comparison of amitriptyline with stabilization splint and placebo in chronic TMD patients: a pilot study. // Acta stomatologica Croatica, 52 (2018), 2; 114-122. doi: 10.15644/asc52/2/4

Podaci o odgovornosti

Alajbeg, Iva ; Borić Brakus, Ratka ; Brakus, Ivan

engleski

Comparison of amitriptyline with stabilization splint and placebo in chronic TMD patients: a pilot study.

Objective of work The authors conducted a clinical study to evaluate the effectiveness of amitriptyline in treatment of chronic TMD patients and to compare treatment results with stabilization splint. Materials and Methods Twenty-one patients with chronic TMD were included and randomly distributed into 3 groups: patients in Group A received amitriptyline, patients in Group B received placebo, and those in Group C were treated with stabilization splint. Treatment outcomes (pain assessed by a visual analogue scale (VAS), maximal comfortable mouth opening (MCO) and oral health related quality of life (OHIP-14)) were taken at baseline (before treatment), and at 1st, 6th and 12th week of treatment. Results No statistically significant differences between the groups at baseline were found (p>0.05). VAS scores improved significantly in Group A (F=11.326, p=0.002, effect size =0.791) and in group C (F=7.343, p=0.005, effect size=0.647). Mean OHIP- 14 scores decreased significantly only in Group A (F=4.417, p=0.036, effect size =0.596). In Group B, VAS and OHIP-14 scores did not change significantly over time. Subjects in Group C had a significant change in MCO relative to Group A and Group B. Conclusion From this pilot study it can be concluded that the use of low doses of amitriptyline for a period of 12 weeks is effective for pain management and quality of life improvement in chronic TMD patients. Stabilization splint demonstrated superiority in the management of limited mouth opening during the same period.

Amitriptyline ; Temporomandibular Joint Disorders ; Occlusal Splints ; Chronic Pain

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

52 (2)

2018.

114-122

objavljeno

0001-7019

1846-0410

10.15644/asc52/2/4

Povezanost rada

Dentalna medicina

Poveznice
Indeksiranost